Editorial - Sofosbuvir/Velpatasvir as a combination with strong potential activity against SARS-CoV2 (COVID-19) infection: how to use direct-acting antivirals as broad-spectrum antiviral agents

Eur Rev Med Pharmacol Sci. 2020 May;24(10):5193-5194. doi: 10.26355/eurrev_202005_21297.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Antiviral Agents / chemistry
  • Antiviral Agents / metabolism
  • Antiviral Agents / therapeutic use*
  • Betacoronavirus / isolation & purification
  • COVID-19
  • Carbamates / therapeutic use*
  • Coronavirus Infections / drug therapy*
  • Coronavirus Infections / virology
  • DNA-Directed DNA Polymerase / chemistry
  • DNA-Directed DNA Polymerase / metabolism
  • Drug Therapy, Combination
  • Heterocyclic Compounds, 4 or More Rings / therapeutic use*
  • Humans
  • Pandemics
  • Pneumonia, Viral / drug therapy*
  • Pneumonia, Viral / virology
  • SARS-CoV-2
  • Sofosbuvir / chemistry
  • Sofosbuvir / metabolism
  • Sofosbuvir / therapeutic use*
  • Viral Proteins / chemistry
  • Viral Proteins / metabolism

Substances

  • Antiviral Agents
  • Carbamates
  • Heterocyclic Compounds, 4 or More Rings
  • Viral Proteins
  • DNA-Directed DNA Polymerase
  • velpatasvir
  • Sofosbuvir